Combined Analysis of ATLAS, FLAIR, ATLAS-2M: Efficacy and Safety of Switch to LA CAB + RPV by BMI Class

October 27-30, 2021; London, United Kingdom
Across phase III/IIIb trials through Week 48, LA CAB + RPV maintained high rates of virologic suppression across dosing strategies and BMI categories; no participant with BMI ≥30 kg/m2 as only baseline risk factor met CVF criterion.
Format: Microsoft PowerPoint (.ppt)
File Size: 194 KB
Released: November 5, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Slides from CCO: Discussion of the implications and considerations of polypharmacy and cardiovascular risk on choice of ART in older PWH

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: November 29, 2021

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for patients with virologic failure and resistance

W. David Hardy, MD Josep M. Llibre, MD, PhD Released: November 29, 2021

Perspective on ART modification to reduce CVD risk in PWH, from Dr Jens D. Lundgren and Clinical Care Options (CCO)

Jens D. Lundgren, MD, DMSc Released: November 29, 2021

One patient’s journey from HIV diagnosis to undetectable while trying to lose weight, from Clinical Care Options (CCO)

person default Anonymous Patient Released: November 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue